Portola Pharmaceuticals signs $150 million royalty agreement
Portola Pharmaceuticals recently signed a $150 million royalty agreement with HealthCare Royalty Partners for Development and Commercialization of Andexanat Alfa, an antidote for Factor Xa inhibitors. Read More »